Table 3.
Univariate and multivariate analyses for 5-year disease-free survival and overall survival
| Variables | 5-year disease-free survival | 5-year overall survival | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate-I | Multivariate-II | Univariate | Multivariate-I | Multivariate-II | |||||||
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
| Pre-neoCRT (n = 104) | ||||||||||||
| Age (≥ 65 vs < 65) | 1.23 (0.58–2.63) | 0.59 | 1.26 (0.53–3.01) | 0.61 | 1.36 (0.58–3.19) | 0.48 | 1.42 (0.57–3.53) | 0.45 | 1.63 (0.59–4.53) | 0.35 | 1.81 (0.67–4.88) | 0.24 |
| cN stage (positive vs. negative) | 1.31 (0.62–2.76) | 0.48 | 0.9 (0.38–2.13) | 0.81 | 0.99 (0.43–2.28) | 0.97 | 1.61 (0.63–4.09) | 0.32 | 1.41 (0.50–3.99) | 0.51 | 1.51 (0.54–4.20) | 0.43 |
| pN stage (positive vs. negative) | 2.67 (1.27–5.62) | 0.01* | 2.55 (1.03–6.32) | 0.04* | 2.37 (0.99–5.67) | 0.05* | 2.05 (0.83–5.11) | 0.12 | 1.95 (0.64–5.92) | 0.24 | 1.87 (0.64–5.52) | 0.26 |
| Clinical response (poor vs. good) | 2.56 (1.16–5.66) | 0.02* | 1.55 (0.60–4.00) | 0.37 | 1.55 (0.60–4.01) | 0.36 | 1.9 (0.75–4.84) | 0.18 | 1.05 (0.33–3.32) | 0.94 | 1.06 (0.33–3.37) | 0.92 |
| TRG (poor vs. good) | 1.76 (0.83–3.73) | 0.14 | 1.76 (0.73–4.23) | 0.21 | 1.72 (0.72–4.12) | 0.22 | 1.88 (0.76–4.62) | 0.17 | 1.94 (0.68–5.57) | 0.22 | 1.93 (0.67–5.53) | 0.22 |
| Tumor PD-L1 (low vs. high) | 2.65 (1.17–6.02) | 0.02* | 2.55 (1.05–6.20) | 0.04* | – | – | 2.59 (0.93–7.21) | 0.07 | 2.37 (0.76–7.38) | 0.14 | – | – |
| IFN-γ/ tumor PD-L1 (L∥L vs. H&H) | 1.76 (0.72–4.35) | 0.22 | – | – | 1.55 (0.62–3.84) | 0.35 | 1.84 (0.61–5.55) | 0.28 | – | – | 1.57 (0.51–4.80) | 0.43 |
| Post-neoCRT (n = 89) | ||||||||||||
| Age (≥ 65 vs < 65) | 1.57 (0.70–3.54) | 0.28 | 1.14 (0.47–2.75) | 0.78 | 1.07 (0.41–2.80) | 0.88 | 1.66 (0.62–4.45) | 0.32 | 0.99 (0.34–2.92) | 0.99 | 1.09 (0.35–3.41) | 0.88 |
| cN stage (POSITIVE vs. negative) | 0.93 (0.42–2.08) | 0.87 | 0.41 (0.16–1.10) | 0.08 | 0.48 (0.19–1.26) | 0.14 | 1.24 (0.46–3.32) | 0.67 | 0.38 (0.10–1.46) | 0.16 | 0.54 (0.15–1.89) | 0.33 |
| pN stage (positive vs. negative) | 2.87 (1.28–6.42) | 0.01* | 4.35 (1.69–11.22) | 0.002* | 3.04 (1.18–7.84) | 0.02* | 2.21 (0.83–5.91) | 0.11 | 3.96 (1.17–13.42) | 0.03* | 2.37 (0.69–8.11) | 0.17 |
| Clinical response (poor vs. good) | 3.3 (1.23–8.85) | 0.02* | 2.48 (0.76–8.10) | 0.13 | 2.18 (0.66–7.18) | 0.2 | 2.37 (0.77–7.36) | 0.13 | 1.66 (0.35–7.99) | 0.53 | 1.4 (0.30–6.55) | 0.67 |
| TRG (poor vs. good) | 1.85 (0.83–4.12) | 0.13 | 2.68 (1.07–6.72) | 0.04* | 2.13 (0.84–5.38) | 0.11 | 2.09 (0.78–5.62) | 0.14 | 3.2 (1.01–10.12) | 0.048* | 2.44 (0.76–7.84) | 0.13 |
| Tumor PD-L1 (low vs. high) | 2.86 (1.27–6.45) | 0.01* | 4.27 (1.62–11.26) | 0.003* | – | – | 6.43 (2.07–19.97) | 0.001* | 10.71 (2.61–43.87) | 0.001* | – | – |
| IFN-γ/ tumor PD-L1 (L∥L vs. H&H) | 2.32 (1.02–5.32) | 0.046* | – | – | 2.51 (1.02–6.19) | 0.046* | 6.25 (1.78–21.96) | 0.004* | – | – | 6.61 (1.72–25.42) | 0.006* |
*p < 0.05
pN stage positive (stage 1a + 1b + 2) vs. negative (stage 0 + X), clinical response good response (complete response and partial response) vs. poor response (stable disease and progressive disease), TRG good response (TRG 3–4) vs. poor response (TRG 1–2), tumor PD-L1 high (grade 2 + 3) vs. low (grade 0 + 1), tumor IFN-γ high (grade 2 + 3) vs. low (grade 0 + 1), IFN-γ/tumor PD-L1 (L∥L vs. H&H) low IFN-γ or tumor PD-L1 vs. high IFN-γ and high PD-L1